Fermenta Biotech Limited
CIN: L99999MH1951PLC008485
Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road,
Majiwade, Thane (W) - 400 610, Maharashtra, India.
Tel. : +91-22-6798 0888 Email : info@fermentabiotech.com,
Website : www.fermentabiotech.com

November 05, 2026

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001
Scrip Code: **506414**

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1,
G Block, Bandra - Kurla Complex,
Bandra (East), Mumbai 400 051
Trading Symbol: **FERMENTA**

Dear Sir,

Sub: Outcome of Board Meeting and Unaudited Financial Results – pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

We write to inform you that the Board of Directors of the Company, at its meeting held on November 05, 2026, has, *inter alia,* approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026.

We are also enclosing herewith the Limited Review Reports on the aforesaid results (Standalone and Consolidated) issued by M/s. SRBC & Co. LLP, Chartered Accountants, Statutory Auditors of the Company with an unmodified opinion on the above-mentioned financial results dated November 05, 2026.

Kindly take the above on record.

The Board meeting commenced at 12:00 p.m. (IST) and concluded at 12:39 p.m. (IST).

Thanking you,

Yours faithfully,
For **Fermenta Biotech Limited**

VARADVINAY AK VIJAY KHAMBETE
Digitally signed by VARADVINAYAK VIJAY KHAMBETE
Date: 2026.11.05 12:48:53 +05'30'

Varadvinayak Khambete
Company Secretary & Head - Legal
Membership No. A33861
Encl: As above

S R B C & CO LLP
Chartered Accountants

12th Floor, The Ruby
29 Senapati Bapat Marg
Dadar (West)
Mumbai - 400 028, India

Tel : +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Fermenta Biotech Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Fermenta Biotech Limited (the "Company") for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003

Poonam Todarwal

S R B C & CO LLP * CHARTERED ACCOUNTANTS * MUMBAI

per Poonam Todarwal
Partner
Membership No.: 136454
UDIN: 26136454VLUFAY2822
Place: Mumbai
Date: November 05, 2026

Fermenta Biotech Limited
CIN:L99999MH1951PLC008485
Regd. Office: A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India.
Tel:+91-22-67980888, Fax:+91-22-67980999,Email: info@fermentabiotech.com, Website: www.fermentabiotech.com

₹ in Lakhs

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

Sr. No.	Particulars	Standalone					
		Quarter Ended			Half Year Ended		Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
1	**Income**						
	a) Revenue from operations (Refer Note 4)	11,693.63	11,183.93	10,711.52	22,877.56	22,613.39	45,025.27
	b) Other income	364.92	489.66	552.79	854.58	1,436.87	2,389.89
2	**Total Income (a+b)**	**12,058.55**	**11,673.59**	**11,264.31**	**23,732.14**	**24,050.26**	**47,415.16**
3	**Expenses**						
	a) Cost of materials consumed (Refer Note 6)	3,162.12	4,485.76	4,151.28	7,647.88	7,330.29	16,656.99
	b) Purchases of stock-in-trade	152.47	130.19	594.41	282.66	1,130.79	1,150.05
	c) Change in inventories of finished goods, stock-in-trade and work-in-progress	724.90	(1,062.56)	(1,490.28)	(337.66)	(581.38)	(2,470.98)
	d) Employee benefits expense	2,080.26	2,005.15	1,872.66	4,085.41	3,769.94	7,413.83
	e) Finance costs	373.30	253.91	258.76	627.21	569.26	1,148.44
	f) Depreciation and amortisation expense	519.83	518.61	513.42	1,038.44	1,068.15	2,093.63
	g) Other expenses	3,169.10	3,327.95	3,286.85	6,497.05	6,414.08	13,195.70
	Total expenses (a to g)	**10,181.98**	**9,659.01**	**9,187.10**	**19,840.99**	**19,701.13**	**39,187.66**
4	**Profit before tax (2-3)**	**1,876.57**	**2,014.58**	**2,077.21**	**3,891.15**	**4,349.13**	**8,227.50**
5	Exceptional items income / (expenses) (Refer Note 7 & 8)	-	-	-	-	-	696.62
6	**Profit after Exceptional Items and before tax (4-5)**	**1,876.57**	**2,014.58**	**2,077.21**	**3,891.15**	**4,349.13**	**8,924.12**
7	Tax expense						
	a) Current tax	454.79	436.09	371.70	890.88	772.08	1,460.72
	b) Deferred tax charge	26.42	79.91	233.72	106.33	481.88	1,035.04
	Total tax expense (a+b)	481.21	516.00	605.42	997.21	1,253.96	2,495.76
8	**Profit for the period/year after tax (6-7)**	**1,395.36**	**1,498.58**	**1,471.79**	**2,893.94**	**3,095.17**	**6,428.36**
9	**Other Comprehensive Income**						
(A)	i) Items that will not be reclassified to Profit or Loss	-	-	-	-	-	32.68
	ii) Income tax thereon	-	-	-	-	-	(8.23)
(B)	Items that will be reclassified to Profit or Loss						
	(i) Net fair value change in investment in equity instruments through other	2.38	(0.68)	(9.42)	1.70	(2.60)	(6.68)
	ii) Income tax thereon.	(0.60)	0.17	0.59	(0.43)	0.59	1.68
	Total other comprehensive Income/(Loss)	**1.78**	**(0.51)**	**(8.83)**	**1.27**	**(2.01)**	**19.45**
10	**Total Comprehensive Income for the period/year (8+9)**	**1,397.14**	**1,498.07**	**1,462.96**	**2,895.21**	**3,093.16**	**6,447.81**
11	Paid-up equity share capital (Face value ₹ 5/- per share)	1,436.37	1,434.03	1,454.83	1,436.37	1,454.83	1,433.53
12	Other equity (excluding revaluation reserve)						40,848.04
13	Earnings per equity share of ₹ 5 each (not annualised)						
	Earnings per equity share of ₹ 5 each before exceptional items						
	a) ₹ Basic	4.86	5.23	5.05	10.09	10.61	20.43
	b) ₹ Diluted	4.77	5.13	5.01	9.90	10.54	20.27
	Earnings per equity share of ₹ 5 each after exceptional items						
	a) ₹ Basic	4.86	5.23	5.05	10.09	10.61	22.13
	b) ₹ Diluted	4.77	5.13	5.01	9.90	10.54	21.96
	See accompanying notes to the Standalone financial results						

FERMENTA BIOTECH LTD. THANE

SIGNED FOR IDENTIFICATION BY
S R B C & CO LLP
MUMBAI

Balance Sheet as at September 30, 2026			₹ in Lakhs	
	PARTICULARS		Standalone	
			Unaudited	Audited
			September 30, 2026	March 31, 2026
	ASSETS			
1	**Non-current assets**			
(a)	Property, plant and equipment		20,261.55	20,550.04
(b)	Capital work-in-progress		2,273.94	1,279.04
(c)	Right of use assets		429.33	492.78
(d)	Investment property (Refer Note 4)		303.60	308.35
(e)	Goodwill		411.65	411.65
(f)	Other Intangible assets		229.66	229.58
(g)	Intangible assets under development		10.74	31.93
(h)	Investments			
	i) Investments in subsidiaries		1,120.06	1,120.06
	ii) Investments in an associate		-	-
(i)	Financial assets			
	i) Investments		43.65	41.94
	ii) Loans		2,675.53	2,318.08
	iii) Other financial assets		605.78	533.04
(j)	Deferred tax assets (net)		1,729.58	1,835.91
(k)	Non-current tax assets		19.99	31.25
(l)	Other non-current assets		305.74	101.33
		Total Non-current assets	**30,420.80**	**29,284.98**
2	**Current assets**			
(a)	Inventories		13,905.32	13,065.56
(b)	Financial assets			
	i) Trade receivables		16,082.14	13,720.56
	ii) Cash and cash equivalents		1,065.16	887.97
	iii) Bank balances other than (ii) above		2,892.62	914.25
	iv) Loans		2.50	2.50
	v) Other financial assets		4,723.40	5,333.75
(c)	Other current assets		1,845.29	2,026.03
		Total Current assets	**40,516.43**	**35,950.62**
		TOTAL ASSETS	**70,937.23**	**65,235.60**
	EQUITY AND LIABILITIES			
1	**EQUITY**			
(a)	Equity Share capital		1,436.37	1,433.53
(b)	Other Equity		42,982.50	40,848.04
	Total Equity		**44,418.87**	**42,281.57**
2	**Non-current liabilities**			
(a)	Financial liabilities			
	i) Borrowings		324.65	789.94
	ii) Lease liabilities		249.28	318.08
	iii) Other financial liabilities		1,673.24	1,671.90
(b)	Provisions		1,012.00	1,019.08
(c)	Other non-current liabilities		4.53	7.89
		Total Non-current liabilities	**3,263.70**	**3,806.89**
3	**Current liabilities**			
(a)	Financial Liabilities			
	i) Borrowings		10,149.13	10,098.62
	ii) Lease liabilities		135.09	126.30
	iii) Trade payables			
	-Total outstanding dues of micro and small enterprises and;		800.50	208.25
	-Total outstanding dues of creditors other than micro enterprises and small enterprises		7,115.92	6,142.39
	iv) Other financial liabilities		646.77	717.99
(b)	Other current liabilities		3,718.49	1,640.73
(c)	Provisions		97.58	97.58
(d)	Current tax liabilities		591.20	115.28
		Total Current liabilities	**23,254.66**	**19,147.14**
		TOTAL EQUITY AND LIABILITIES	**70,937.23**	**65,235.60**

FERMENTA BIOTECH LTD. THANE

SIGNED FOR IDENTIFICATION BY

S R B C & CO LLP
MUMBAI

NOTES:

1. Segment Information

₹ in Lakhs

Particulars	Standalone					
	Quarter Ended			Half Year Ended		Year Ended
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
Segment revenue						
- Bulk drugs/chemicals	11,733.80	11,341.96	10,101.40	23,075.76	21,773.83	44,372.65
- Property (Refer Note 4)	198.38	199.36	200.62	397.74	555.84	951.27
- Unallocated (Refer Note 5)	126.37	132.27	962.29	258.64	1,720.59	2,091.24
Total Income	**12,058.55**	**11,673.59**	**11,264.31**	**23,732.14**	**24,050.26**	**47,415.16**
Segment results						
- Bulk drugs/chemicals (Refer Note 6)	2,122.33	2,129.38	1,990.26	4,251.71	4,205.71	8,260.73
- Property	1.17	6.84	22.16	8.01	179.11	210.98
- Unallocated (Net) (Refer Note 5)	126.37	132.27	323.55	258.64	533.57	904.23
Total Profit before tax and finance cost	**2,249.87**	**2,268.49**	**2,335.97**	**4,518.36**	**4,918.39**	**9,375.94**
- Finance costs	(373.30)	(253.91)	(258.76)	(627.21)	(569.26)	(1,148.44)
Total Profit before Exceptional item and tax	**1,876.57**	**2,014.58**	**2,077.21**	**3,891.15**	**4,349.13**	**8,227.50**
- Exceptional item (Refer Note 7 & 8)	-	-	-	-	-	696.62
Total Profit before tax	**1,876.57**	**2,014.58**	**2,077.21**	**3,891.15**	**4,349.13**	**8,924.12**
Segment Assets						
- Bulk drugs/chemicals	56,636.70	54,075.00	50,744.77	56,636.70	50,744.77	52,996.08
- Property	1,118.73	862.58	2,171.34	1,118.73	2,171.34	856.88
- Unallocated*	13,181.80	12,709.51	12,522.59	13,181.80	12,522.59	11,382.64
Total Segment Assets	**70,937.23**	**67,647.09**	**65,438.70**	**70,937.23**	**65,438.70**	**65,235.60**
Segment Liabilities						
- Bulk drugs/chemicals	10,185.43	9,451.18	9,489.00	10,185.43	9,489.00	8,971.77
- Property	5,196.81	3,894.07	4,166.21	5,196.81	4,166.21	2,907.36
- Unallocated*	11,136.12	10,409.27	11,531.25	11,136.12	11,531.25	11,074.90
Total Segment Liabilities	**26,518.36**	**23,754.52**	**25,186.46**	**26,518.36**	**25,186.46**	**22,954.03**

(*Refer Note 5 for transfer of assets and liabilities pertaining to the Environment Division).

FERMENTA BIOTECH LTD. THANE

SIGNED FOR IDENTIFICATION BY

S R B C & CO LLP
MUMBAI

Statement of Cash Flows		₹ in Lakhs	
		Standalone	
		Half Year Ended	
	Particulars	Unaudited	Unaudited
		September 30, 2026	September 30, 2025
A)	**CASH FLOWS FROM OPERATING ACTIVITIES**		
	Profit after Exceptional Items and before tax	3,891.15	4,349.13
	Adjustments for:		
	Depreciation and amortisation expense	1,038.44	1,068.15
	Net unrealised foreign exchange (gain) / loss	(140.60)	434.25
	(Gain on sale) / loss, write off of property, plant and equipment and investment property (net)	32.02	(173.68)
	Proceeds on sale of Investment Property	-	163.20
	Expected credit loss on financial asset	99.88	93.65
	Unwinding of interest on financial assets carried at amortised cost	(3.24)	(2.94)
	Share based payments to employees	270.20	142.93
	Finance costs	627.21	569.26
	Interest income	(296.62)	(278.53)
	Dividend income	(0.44)	-
	Liabilities / provisions no longer required written back (net)	(303.19)	(151.98)
	Provisions no longer required written back of inventory (refer note 6)	(205.00)	(505.55)
	Net (gain) / Loss on fair value changes of derivatives measured at FVTPL	(38.81)	234.85
	Operating Profit before working capital changes	**4,971.00**	**5,942.74**
	Movements in working capital:		
	(Increase) in trade receivables	(1,657.45)	(1,324.27)
	(Increase) in inventories	(634.76)	(1,575.54)
	Decrease in other assets	43.45	427.30
	Increase in trade payables	1,914.92	639.30
	(Decrease) / Increase in provisions	(7.08)	85.07
	Increase in other liabilities	2,003.21	126.78
		6,633.29	**4,321.38**
	Income taxes payment net of refund	(403.70)	(745.97)
	Net cash generated from operations (A)	**6,229.59**	**3,575.41**
B)	**CASH FLOWS FROM INVESTING ACTIVITIES**		
	Payments for purchase of property, plant and equipment, investment property, capital work-in-progress, intangible assets and intangible assets under development	(1,730.16)	(1,253.70)
	Proceeds on sale of property, plant and equipment	3.35	10.92
	Repayment of loan given to employee	1.00	5.29
	Interest received	75.28	178.04
	Loan given to subsidiary	(350.00)	-
	Investments in subsidiary	-	(10.00)
	Dividend received	0.44	-
	Bank Deposits (placed) / realised	(1,180.00)	(1,915.63)
	Net cash (used in) investing activities (B)	**(3,180.09)**	**(2,985.08)**
C)	**CASH FLOWS FROM FINANCING ACTIVITIES**		
	Proceeds from non current borrowings	-	43.04
	Repayment of non current Borrowings	(1,161.48)	(70.68)
	Treasury shares acquired by ESOP trust	-	(246.23)
	Proceeds on issue of equity share on stock option exercise	47.41	-
	Proceeds / (Repayment) of current borrowings (net)	(103.90)	1,107.14
	Finance cost paid	(634.55)	(542.20)
	Repayment of Lease Liabilities	(76.57)	(72.93)
	Dividends paid	(1,075.52)	(729.22)
	Net cash (used in) financing activites (C)	**(3,004.61)**	**(511.08)**
	Net increase in cash and cash equivalents (A)+(B)+(C)	**44.89**	**79.25**
	Less: Decrease in cash & cash equivalents classified within assets held for sale (Refer Note 5)	-	**(150.00)**
	Net increase /(decrease) in cash and cash equivalents	**44.89**	**(70.75)**
	Cash and cash equivalents at the beginning of the year	(863.82)	(311.65)
	Cash and cash equivalents at the end of the period	**(818.93)**	**(382.40)**
	Components of cash and cash equivalents		
	Cash on hand	21.82	18.28
	Balances with banks		
	In current accounts	1,043.34	1,200.88
	In deposit accounts with original maturity for less than 3 months	-	-
	Cash and cash equivalents	1,065.16	1,219.16
	Bank overdraft/Cash credit facilities	(1,884.09)	(1,601.56)
	Total cash and cash equivalents considered for cash flows	**(818.93)**	**(382.40)**

FERMENTA BIOTECH LTD THANE

SIGNED FOR IDENTIFICATION BY

S R B C & CO LLP
MUMBAI

2 The above unaudited standalone financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 05th November, 2026. The results of the Company are available for investors at www.fermentabiotech.com, www.bseindia.com and www.nseindia.com in accordance with the provision of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

3 These unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

4 During the previous year, the company sold a portion of its investment property comprising freehold land situated at Village Takawe. The gain arising from such sale amounted to ₹Nil lakhs for the quarter ended September 30, 2026, the half year ended September 30, 2026 and for the quarter ended June 30, 2026 (quarter ended September 30, 2025: ₹Nil lakhs; half year ended September 30, 2025: ₹162.89 lakhs and for the year ended March 31, 2026 amounted to ₹162.89 lakhs). The said income has been recognized under 'Revenue from Operations' pertaining to the Property Segment.

5 During the previous year, the company transferred its Environment Division to its wholly owned subsidiary, Fermenta Environment Solutions Private Limited, as a going concern on a slump sale basis with effect from October 01, 2025, for a consideration of ₹ 1,900 lakhs.

6 During the current period, the company has consumed semi-finished inventory provided for in the earlier year towards the production of animal feed and accordingly such provision has been reversed for the quarter ended September 30, 2026 ₹ Nil lakhs, for the quarter ended June 30, 2026 and for the half year ended September 30, 2026 ended is ₹ 205.00 lakhs(quarter ended September 30, 2025 and for the half year ended September 30, 2025: ₹505.55 lakhs and for the year ended March 31, 2026 is ₹ 1,023.73 lakhs).

7 In the earlier years, the company had recognised provision against certain receivables and trade receivables. The company recovered part amount of ₹ 907.14 lakhs against these provided balances and accordingly such provision was reversed and recorded as an exceptional items in the year ended March 31, 2026.

8 During the previous year, the company assessed the potential impact of increased employee benefit obligations arising from the implementation of the Labour Codes, based on its best estimate and in consultation with external experts. Accordingly, the Company recognised a provision of ₹210.52 lakhs for the year ended March 31, 2026 in accordance with Ind AS 19, Employee Benefits, which was disclosed as exceptional item.

9 Figures of the previous periods have been regrouped/ reclassified wherever necessary to conform to the current period classification.

FERMENTA BIOTECH LTD. THANE

Prashant Nagre
Managing Director
DIN-09165447

SIGNED FOR IDENTIFICATION BY
S R B C & CO LLP
MUMBAI

Place: Thane
Date : 05th November, 2026

S R B C & CO LLP
Chartered Accountants

12th Floor, The Ruby
29 Senapati Bapat Marg
Dadar (West)
Mumbai - 400 028, India

Tel : +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Fermenta Biotech Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Fermenta Biotech Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its associate for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

S. No.	Name of the Entity	Relationship
1	Fermenta Biotech Limited	Parent
2	Fermenta Biotech (UK) Limited	Subsidiary
3	Fermenta Biotech GmbH	Subsidiary
4	Fermenta Biotech USA LLC	Subsidiary
5	Fermenta USA LLC	Subsidiary
6	Fermenta Environment Solutions Private Limited	Subsidiary
7	Health and Wellness India Private Limited	Associate

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

S R B C & CO LLP * MUMBAI * CHARTERED ACCOUNTANTS

6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:

   3 subsidiaries, whose unaudited interim financial results include total assets of Rs. 3,635.56 lakhs as at September 30, 2026, total revenues of Rs. 1,728.31 lakhs and Rs. 3,376.47 lakhs, total net loss after tax of Rs. (271.36) lakhs and Rs. (669.53) lakhs, total comprehensive loss of Rs. (271.36) lakhs and Rs. (669.53) lakhs, for the quarter ended September 30, 2026 and the period ended on that date respectively, and net cash outflows of Rs. 55.05 lakhs for the period from April 01, 2026 to September 30, 2026, as considered in the Statement which have been reviewed by their respective independent auditors.

   The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

7. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:

   - 1 subsidiary, whose interim financial results and other financial information reflect total assets of Rs. 51.01 lakhs as at September 30, 2026, total revenues of NIL and NIL, total net profit after tax of Rs. 0.57 lakhs and Rs. 0.49 lakhs, total comprehensive income of Rs. 0.57 lakhs and Rs. 0.49 lakhs, for the quarter ended September 30, 2026 and the period ended on that date respectively and net cash outflows of Rs. 0.66 lakhs for the period from April 01, 2026 to September 30, 2026.

   - 1 associate, whose interim financial results includes the Group's share of net profit of Rs. Nil and Rs. Nil and Group's share of total comprehensive income of Rs. Nil and Rs. Nil for the quarter ended September 30, 2026 and for the period ended on that date respectively.

   The unaudited interim financial results and other unaudited financial information of the these subsidiaries and associate have not been reviewed by their auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries and associate, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

   Our conclusion on the Statement in respect of matters stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

For S R B C & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003

Poonam Todarwal

S R B C & CO LLP * MUMBAI * CHARTERED ACCOUNTANTS

per Poonam Todarwal
Partner
Membership No.: 136454
UDIN: 26136454CZW04085 92
Place: Mumbai
Date: November 05, 2026

Fermenta Biotech Limited
CIN:L99999MH1951PLC008485
Regd. Office: A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India.
Tel:+91-22-67980888, Fax:+91-22-67980999,Email: info@fermentabiotech.com, Website: www.fermentabiotech.com

₹ in Lakhs

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

Sr. No.	Particulars	Consolidated					
		Quarter Ended			Half Year Ended		Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
1	**Income**						
	a) Revenue from operations (Refer Note 4)	13,267.44	12,182.12	13,022.27	25,449.56	26,648.54	52,542.94
	b) Other income	308.26	437.38	543.29	745.64	1,420.42	2,238.52
2	**Total Income (a+b)**	**13,575.70**	**12,619.50**	**13,565.56**	**26,195.20**	**28,068.96**	**54,781.46**
3	**Expenses**						
	a) Cost of materials consumed (Refer Note 5)	3,590.67	3,875.32	3,282.49	7,465.99	6,034.32	14,875.93
	b) Purchases of stock-in-trade	657.76	978.04	1,662.74	1,635.80	3,224.95	4,364.20
	c) Change in inventories of finished goods, stock-in-trade and work-in-progress	1,015.38	(647.34)	(289.18)	368.04	595.70	(47.02)
	d) Employee benefits expense	2,374.35	2,300.62	2,014.46	4,674.97	4,049.46	8,259.43
	e) Finance costs	373.30	253.91	257.94	627.21	568.44	1,153.76
	f) Depreciation and amortisation expense	520.64	519.56	540.51	1,040.20	1,121.74	2,169.68
	g) Other expenses	3,618.66	3,870.24	3,688.26	7,488.90	7,257.30	15,107.01
	Total expenses (a to g)	**12,150.76**	**11,150.35**	**11,157.22**	**23,301.11**	**22,851.91**	**45,882.99**
4	**Profit before tax (2-3)**	**1,424.94**	**1,469.15**	**2,408.34**	**2,894.09**	**5,217.05**	**8,898.47**
5	Exceptional Items income / (expenses) (Refer Note 6 & 7)	-	-	-	-	-	687.58
6	**Profit after Exceptional Items and before tax (4-5)**	**1,424.94**	**1,469.15**	**2,408.34**	**2,894.09**	**5,217.05**	**9,586.05**
7	Tax expense						
	a) Current tax	454.80	436.09	371.70	890.89	772.08	1,525.58
	b) Deferred tax charge	26.42	79.91	233.72	106.33	481.88	1,035.04
	Total tax expense (a+b)	**481.22**	**516.00**	**605.42**	**997.22**	**1,253.96**	**2,560.62**
8	**Profit for the period /year after tax but before share of profit of an associate (6-7)**	943.72	953.15	1,802.92	1,896.87	3,963.09	7,025.43
9	Share of profit of an associate	-	-	-	-	-	-
10	**Net Profit after tax (8-9)**	**943.72**	**953.15**	**1,802.92**	**1,896.87**	**3,963.09**	**7,025.43**
11	Attributable to:						
	- Owners of the parent	977.03	973.81	1,887.81	1,950.84	4,071.30	7,176.53
	- Non-controlling interests	(33.31)	(20.66)	(84.89)	(53.97)	(108.21)	(151.10)
12	**Other Comprehensive Income**						
	Items that will not be reclassified to Profit or Loss						
	i) Remeasurements of defined benefit plan	-	-	-	-	-	36.63
	ii) Income tax thereon	-	-	-	-	-	(8.23)
	Items that will be reclassified to Profit or Loss						
	i) Exchange differences in translating the financials statements in foreign currency	(41.40)	30.20	(151.21)	(11.20)	(424.32)	(684.31)
	ii) Net fair value change in investment in equity instruments through other comprehensive income (net)	2.38	(0.68)	(9.42)	1.70	(2.60)	(6.68)
	iii) Income tax thereon.	(0.60)	0.17	0.59	(0.43)	0.59	1.68
	Total other comprehensive Income	**(39.62)**	**29.69**	**(160.04)**	**(9.93)**	**(426.33)**	**(660.91)**
13	**Total Comprehensive Income for the period/year (10+12)**	904.10	982.84	1,642.88	1,886.94	3,536.76	6,364.52
	Attributable to:						
	- Owners of the parent	937.41	1,003.50	1,727.77	1,940.91	3,644.97	6,515.62
	- Non-controlling Interests	(33.31)	(20.66)	(84.89)	(53.97)	(108.21)	(151.10)
14	Paid-up equity share capital (Face value ₹ 5/- per share)	1,436.37	1,434.03	1,454.83	1,436.37	1,454.83	1,433.53
15	Other equity (excluding revaluation reserve)						39,187.85
16	Earnings per equity share of ₹ 5 each (not annualised)						
	Earnings per equity share of ₹ 5 each before exceptional items						
	a) ₹ Basic	3.41	3.40	6.48	6.80	13.96	23.02
	b) ₹ Diluted	3.34	3.34	6.43	6.67	13.87	22.16
	Earnings per equity share of ₹ 5 each after exceptional items						
	a) ₹ Basic	3.40	3.40	6.48	6.80	13.96	24.70
	b) ₹ Diluted	3.34	3.34	6.43	6.67	13.87	24.51
	See accompanying notes to the Consolidated financial results						

FERMENTA BIOTECH LTD. THANE

SIGNED FOR IDENTIFICATION BY

S R B C & CO LLP
MUMBAI

Balance Sheet as at September 30, 2026			₹ in Lakhs	
	PARTICULARS		Consolidated	
			Unaudited	Audited
			September 30, 2026	March 31, 2026
	ASSETS			
1	**Non-current assets**			
(a)	Property, plant and equipment		20,271.98	20,562.04
(b)	Capital work-in-progress		2,274.13	1,279.04
(c)	Right of use assets		429.33	492.77
(d)	Investment property (Refer Note 4)		303.59	308.34
(e)	Goodwill		411.65	411.65
(f)	Other Intangible assets		229.66	229.76
(g)	Intangible assets under development		10.74	31.93
(h)	Investments			
	Investments in an associate		-	-
(i)	Financial assets			
	i) Investments		43.65	41.94
	ii) Trade receivables		428.79	-
	iii) Loans		114.20	115.94
	iv) Other financial assets		608.17	534.52
(j)	Deferred tax assets (net)		1,729.57	1,835.91
(k)	Non-current tax assets		65.65	46.52
(l)	Other non-current assets		306.97	101.33
		Total Non-current assets	**27,228.08**	**25,991.69**
2	**Current assets**			
(a)	Inventories		16,688.61	15,253.97
(b)	Financial assets			
	i) Trade receivables		12,010.32	11,159.08
	ii) Cash and cash equivalents		2,967.64	3,169.46
	iii) Bank balances other than (ii) above		2,943.23	964.85
	iv) Loans		8.14	6.83
	v) Other financial assets		4,623.30	5,324.74
(c)	Other current assets		2,511.89	2,358.26
(d)	Contract Assets		585.17	565.02
		Total Current assets	**42,338.30**	**38,802.21**
		TOTAL ASSETS	**69,566.38**	**64,793.90**
	EQUITY AND LIABILITIES			
1	**EQUITY**			
(a)	Equity Share capital		1,436.37	1,433.53
(b)	Other Equity		40,375.74	39,187.85
	Equity attributable to the owners of the Company		**41,812.11**	**40,621.38**
(c)	**Non-controlling interests**		**(602.80)**	**(566.79)**
		Total Equity	**41,209.31**	**40,054.59**
2	**Non-current liabilities**			
(a)	Financial liabilities			
	i) Borrowings		324.64	789.93
	ii) Lease liabilities		249.28	318.08
	iii) Other financial liabilities		1,673.24	1,671.90
(b)	Provisions		1,066.76	1,074.08
(c)	Other non-current liabilities		4.53	7.89
		Total Non-current liabilities	**3,318.45**	**3,861.88**
3	**Current liabilities**			
(a)	Financial Liabilities			
	i) Borrowings		10,149.13	10,098.61
	ii) Lease liabilities		135.09	126.30
	iii) Trade payables			
	-Total outstanding dues of micro and small enterprises and;		1,082.67	450.86
	-Total outstanding dues of creditors other than micro enterprises and small enterprises		8,173.03	7,264.18
	iv) Other financial liabilities		712.84	775.01
(b)	Other current liabilities		3,810.10	1,703.99
(c)	Provisions		109.21	101.21
(d)	Current tax liabilities		660.10	184.27
(e)	Contract Liability		206.45	173.00
		Total Current liabilities	**25,038.62**	**20,877.43**
		TOTAL EQUITY AND LIABILITIES	**69,566.38**	**64,793.90**

FERMENTA BIOTECH LTD. THANE

SIGNED FOR IDENTIFICATION BY

S R B C & CO LLP
MUMBAI

NOTES:

1. Segment Information ₹ in Lakhs

Particulars	Consolidated					
	Quarter Ended			Half Year Ended		Year Ended
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
Segment revenue						
- Bulk drugs/chemicals	12,230.79	11,739.16	12,402.63	23,969.95	25,792.52	51,472.17
- Property (Refer Note 4)	198.38	199.36	200.62	397.74	555.84	951.27
- Environment (Refer Note 10)	1,071.87	599.01	860.45	1,670.88	1,526.68	1,927.21
- Unallocated	74.66	81.97	101.86	156.63	193.92	430.81
Total Income	**13,575.70**	**12,619.50**	**13,565.56**	**26,195.20**	**28,068.96**	**54,781.46**
Segment results						
- Bulk drugs/chemicals (Refer Note 5)	1,897.91	1,905.05	2,655.15	3,802.96	5,756.89	10,107.76
- Property	1.17	6.84	22.16	8.01	179.11	210.98
- Environment (Refer Note 10)	(175.50)	(270.80)	(112.89)	(446.30)	(344.43)	(697.32)
- Unallocated	74.66	81.97	101.86	156.63	193.92	430.81
Total Profit before tax and finance cost	**1,798.24**	**1,723.06**	**2,666.28**	**3,521.30**	**5,785.49**	**10,052.23**
- Finance costs	(373.30)	(253.91)	(257.94)	(627.21)	(568.44)	(1,153.76)
Total Profit before Exceptional item and tax	**1,424.94**	**1,469.15**	**2,408.34**	**2,894.09**	**5,217.05**	**8,898.47**
- Exceptional item (Refer Note 6 & 7)	-	-	-	-	-	687.58
Total Profit before tax	**1,424.94**	**1,469.15**	**2,408.34**	**2,894.09**	**5,217.05**	**9,586.05**
Segment Assets						
- Bulk drugs/chemicals	55,358.49	52,962.55	50,446.11	55,358.49	50,446.11	52,329.04
- Property	1,118.73	862.58	2,171.34	1,118.73	2,171.34	856.88
- Environment (Refer Note 10)	2,529.41	2,291.89	2,274.35	2,529.41	2,274.35	2,425.33
- Unallocated	10,559.75	10,477.20	10,248.25	10,559.75	10,248.25	9,182.65
Total Segment Assets	**69,566.38**	**66,594.22**	**65,140.05**	**69,566.38**	**65,140.05**	**64,793.90**
Segment Liabilities						
- Bulk drugs/chemicals	11,134.42	10,300.10	10,890.48	11,134.42	10,890.48	9,903.30
- Property	5,196.81	3,894.07	4,166.21	5,196.81	4,166.21	2,907.36
- Environment (Refer Note 10)	992.93	1,003.91	415.66	992.93	415.66	853.77
- Unallocated	11,032.91	10,245.81	11,115.56	11,032.91	11,115.56	11,074.88
Total Segment Liabilities	**28,357.07**	**25,443.89**	**26,587.91**	**28,357.07**	**26,587.91**	**24,739.31**

FERMENTA BIOTECH LTD. THANE

SIGNED FOR IDENTIFICATION BY

S R B C & CO LLP
MUMBAI

Statement of Cash Flows		₹ in Lakhs	
		Consolidated	
		Half Year Ended	
	Particulars	Unaudited	Unaudited
		September 30, 2026	September 30, 2025
A)	**CASH FLOWS FROM OPERATING ACTIVITIES**		
	Profit after Exceptional Items and before tax	2,894.09	5,217.05
	Adjustments for:		
	Depreciation and amortisation expense	1,040.20	1,121.74
	Net unrealised foreign exchange loss /(gain)	(143.95)	5.96
	(Gain on sale) / loss, write off of property, plant and equipment and investment property (net)	32.02	(162.89)
	Proceeds on sale of Investment Property	-	174.12
	Expected credit loss on financial asset	152.36	93.65
	Share based payments to employees	274.33	142.93
	Finance costs	627.21	568.44
	Interest income	(207.47)	(259.27)
	Dividend income	(0.44)	-
	Unwinding of interest on financial assets carried at amortised cost	(3.24)	(2.94)
	Liabilities / provisions no longer required written back (net)	(312.88)	(152.05)
	Provisions no longer required written back of inventory (refer note 5)	(205.00)	(505.55)
	Net (gain) / loss on fair value changes of derivatives measured at FVTPL	(38.81)	234.85
	Operating Profit before working capital changes	**4,108.42**	**6,476.04**
	Movements in working capital:		
	(Increase) in trade receivables	(628.38)	(2,261.03)
	(Increase) in inventories	(1,229.64)	(1,065.68)
	(Increase)/Decrease in other assets	(311.89)	503.32
	Increase in trade payables	1,900.17	461.00
	Increase in provisions	0.68	313.87
	Increase in other liabilities	2,074.04	122.78
		5,913.40	**4,550.30**
	Income taxes payment net of refund	(434.19)	(745.97)
	Net cash generated from operations (A)	**5,479.21**	**3,804.33**
B)	**CASH FLOWS FROM INVESTING ACTIVITIES**		
	Payments for purchase of property, plant and equipment, investment property, capital work-in-progress, intangible assets and intangible assets under development	(1,731.60)	(1,242.29)
	Proceeds on sale of property, plant and equipment	3.35	10.92
	Repayment of loan given to employee	3.43	5.29
	Interest received	77.12	178.04
	Loan given to employees	(3.00)	-
	Dividend received	0.44	-
	Bank Deposits (placed) / realised	(1,180.00)	(1,915.64)
	Net cash (used in) investing activities (B)	**(2,830.26)**	**(2,963.68)**
C)	**CASH FLOWS FROM FINANCING ACTIVITIES**		
	Proceeds from non current borrowings	-	43.04
	Repayment of non current Borrowings	(1,161.48)	(70.68)
	Treasury shares acquired by ESOP trust	-	(246.23)
	Proceeds on issue of equity share on stock option exercise	47.41	-
	Proceeds on issue of Equity shares of subsidiary (Refer Note 8)	21.54	-
	Proceeds / (Repayment) of current borrowings (net)	(103.90)	1,107.14
	Finance cost paid	(634.55)	(544.23)
	Repayment of Lease Liabilities	(76.57)	(72.92)
	Dividends paid	(1,075.52)	(729.23)
	Net cash (used in) financingactivites (C)	**(2,983.07)**	**(513.11)**
	Net (decrease) / increase in cash and cash equivalents (A)+(B)+(C)	**(334.12)**	**327.54**
	Cash and cash equivalents at the beginning of the year	1,417.67	662.79
	Cash and cash equivalents at the end of the period	**1,083.55**	**990.33**
	Components of cash and cash equivalents		
	Cash on hand	23.24	28.28
	Balances with banks		
	In current accounts	2,944.40	2,563.61
	In deposit accounts with original maturity for less than 3 months	-	-
	Cash and cash equivalents	2,967.64	2,591.89
	Bank overdraft/Cash credit facilities	(1,884.09)	(1,601.56)
	Total cash and cash equivalents considered for cash flows	**1,083.55**	**990.33**

FERMENTA BIOTECH LTD. THANE

SIGNED FOR IDENTIFICATION BY

S R B C & CO LLP
MUMBAI

2 The above unaudited consolidated financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 05th November, 2026.The results of the Company are available for investors at www.fermentabiotech.com, www.bseindia.com and www.nseindia.com in accordance with the provision of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

3 These unaudited consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

4 During the previous year, the Parent company sold a portion of its investment property comprising freehold land situated at Village Takawe. The gain arising from such sale amounted to ₹Nil lakhs for the quarter ended September 30, 2026, the half year ended September 30, 2026 and for the quarter ended June 30, 2026 (quarter ended September 30, 2025: ₹Nil lakhs; half year ended September 30, 2025: ₹162.89 lakhs and for the year ended March 31, 2026 amounted to ₹162.89 lakhs). The said income has been recognized under 'Revenue from Operations' pertaining to the Property Segment.

5 During the current period, the Parent company has consumed semi-finished inventory provided for in the earlier year towards the production of animal feed and accordingly such provision has been reversed for the quarter ended September 30, 2026 ₹ Nil lakhs, for the quarter ended June 30, 2026 and for the half year ended September 30, 2026 ended is ₹ 205.00 lakhs (quarter ended September 30, 2025 and for the half year ended September 30, 2025: ₹505.55 lakhs and for the year ended March 31, 2026 is ₹ 1,023.73 lakhs).

6 In the earlier years, the Parent company had recognised provision against certain receivables and trade receivables. The Parent company recovered part amount of ₹ 907.14 lakhs against these provided balances and accordingly such provision was reversed and recorded as an exceptional items in the year ended March 31, 2026.

7 During the previous year, the Group assessed the potential impact of increased employee benefit obligations arising from the implementation of the Labour Codes, based on its best estimate and in consultation with external experts. Accordingly, the Group recognised a provision of ₹219.56 lakhs for the year ended March 31, 2026 in accordance with Ind AS 19, Employee Benefits, which was disclosed as exceptional item.

8 During the quarter, Subsidiary of the Company Fermenta Environment Solutions Private Limited (FESPL) has issued 7,17,949 new Equity shares under Private Placement at a price of ₹12 per equity share as per term and condition set out in the shareholder agreement. Company received 25 % subscription amount to ₹ 21.53 lakhs.

9 During the quarter, Subsidiary of the Company Fermenta Environment Solutions Private Limited (FESPL) has granted 1,578,945 employee stock options to the eligible employees of the company at an exercise price of ₹ 10.00 per option exercisable into equivalent equity share of ₹10 each subject to the fulfilment of vesting conditions, under "The Fermenta Environment Solutions Private Limited - Employee Stock Option Plan 2026'

10 During the quarter, the company identified the "Environment" business as a separate reportable segment, as it met the quantitative threshold prescribed under Ind AS 108, Operating Segments.

11 Figures of the previous periods have been regrouped/ reclassified wherever necessary to conform to the current period classification.

FERMENTA BIOTECH LTD. THANE

Place: Thane
Date : 05th November, 2026

Prashant Nagre
Managing Director
DIN-09165447

SIGNED FOR IDENTIFICATION BY

S R B C & CO LLP
MUMBAI